



## Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025

WALTHAM, Mass., May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:

**Event: Jefferies Global Healthcare Conference**

**Date:** Wednesday, June 4, 2025

**Fireside Time:** 8:10am ET

**Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025**

**Date:** Monday, June 9, 2025

**Fireside Time:** 9:20am ET

Live audio webcasts and replays of these events will be available on the Spyre investor events website at <https://ir.spyre.com/events-and-presentations>.

### About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting  $\alpha 4\beta 7$ , TL1A, and IL-23. For more information, visit Spyre's website at [www.spyre.com](http://www.spyre.com).

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

SOURCE Spyre Therapeutics, Inc.